ConductScience.org, home

Paper5823930

The synthesis of mouse hemoglobin beta-chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA.

Lockard RE and 1 other. Biochem Biophys Res Commun, 1969. Cited by 253 papers, by iCite.

Cite this record

ConductScience Library. The synthesis of mouse hemoglobin beta-chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA. Papers, record 5823930. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5823930

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The synthesis of mouse hemoglobin beta-chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA.
PubMed
Journal
Biochem Biophys Res Commun
PubMed
Year
1969
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
253
iCite
Revised in PubMed
2019-06-12
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lockard RER E
2Lingrel JBJ B

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HemoglobinsMajor topic
Peptide BiosynthesisMajor topic
RNA, MessengerMajor topic
ReticulocytesMajor topic
Animals
Carbon Isotopes
Cell-Free System
Centrifugation, Density Gradient
Chromatography, Ion Exchange
Globins
Leucine
Mice
Peptides
Rabbits
Ribosomes
Tritium

Source PubMed

Download CSV of topics

Cited by60

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 253 citations.

PMIDTitleJournalYearIn PapersSource
42728430Structural evolution of ionizable lipids for nucleic acid delivery.Nat Rev Chem2026https://conductscience.org/library/papers/42728430PubMed
41981145mRNA medicine for cardiovascular disease.Nat Cardiovasc Res2026https://conductscience.org/library/papers/41981145PubMed
40881859Unraveling the potential: mRNA therapeutics in oncology.Front Oncol2025https://conductscience.org/library/papers/40881859PubMed
40243757In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines.Int J Mol Sci2025https://conductscience.org/library/papers/40243757PubMed
40195623Engineering Lipid Nanoparticles for mRNA Immunotherapy.Wiley Interdiscip Rev Nanomed Nanobiotechnol2025https://conductscience.org/library/papers/40195623PubMed
39543114Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39543114PubMed
39179112Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies.J Control Release2024https://conductscience.org/library/papers/39179112PubMed
39171210Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology.Precis Clin Med2024https://conductscience.org/library/papers/39171210PubMed
39027251Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders.Acta Pharm Sin B2024https://conductscience.org/library/papers/39027251PubMed
37834268The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics.Int J Mol Sci2023https://conductscience.org/library/papers/37834268PubMed
37794448Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy.J Transl Med2023https://conductscience.org/library/papers/37794448PubMed
37726283mRNA vaccines in disease prevention and treatment.Signal Transduct Target Ther2023https://conductscience.org/library/papers/37726283PubMed
37656402mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond.Eur J Drug Metab Pharmacokinet2023https://conductscience.org/library/papers/37656402PubMed
37470024Messenger RNA-Based Therapeutics and Vaccines: What's beyond COVID-19?ACS Pharmacol Transl Sci2023https://conductscience.org/library/papers/37470024PubMed
36932293mRNA therapy at the convergence of genetics and nanomedicine.Nat Nanotechnol2023https://conductscience.org/library/papers/36932293PubMed
36678793mRNA in the Context of Protein Replacement Therapy.Pharmaceutics2023https://conductscience.org/library/papers/36678793PubMed
36471724Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics.Bioact Mater2023https://conductscience.org/library/papers/36471724PubMed
36224645Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine.Mil Med Res2022https://conductscience.org/library/papers/36224645PubMed
35424872A brief review of mRNA therapeutics and delivery for bone tissue engineering.RSC Adv2022https://conductscience.org/library/papers/35424872PubMed
35322018Advances in COVID-19 mRNA vaccine development.Signal Transduct Target Ther2022https://conductscience.org/library/papers/35322018PubMed

See all 60 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/5823930

GET https://conductscience.org/api/papers/v1/5823930/cited_by?page=2